APP
RCUS icon

Alpha Paradigm Partners’s Arcus Biosciences RCUS Stock Holding History

Alpha Paradigm Partners’s Portfolio RCUS Stock Details RCUS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-66,508
Closed -$2.1M – 613
2022
Q1 		$2.1M Buy
+66,508
New +$2.23M 0.83% 10
2021
Q4 		– Sell
-53,910
Closed -$1.88M – 646
2021
Q3 		$1.88M Sell
53,910
-18,041
-25% -$561K 0.75% 14
2021
Q2 		$1.98M Buy
+71,951
New +$2.06M 0.75% 12

Other funds holding RCUS

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return
PAMS
Pictet Asset Management (Switzerland) Geneva 73, Switzerland $84.3B AUM 26.5% 1-Year Est. Return
IFA
Invus Financial Advisors New York $89.2M AUM 10.79% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

Alpha Paradigm Partners's RCUS Position: Q2 2022 in Review

Alpha Paradigm Partners sold out of Arcus Biosciences (RCUS) in Q2 2022, closing a stake of 66,508 shares — an estimated $2.1M sold.

Alpha Paradigm Partners first reported a position in RCUS in Q2 2021 and held it in 3 quarters. The position peaked at $2.1M in Q1 2022. 173 funds tracked by Wall St. Rank hold RCUS as of Q2 2022.

  • Alpha Paradigm Partners reported no remaining Arcus Biosciences position as of Q2 2022 after selling out during the quarter.
  • Alpha Paradigm Partners sold 66,508 Arcus Biosciences shares in Q2 2022, an estimated $2.1M.
  • Alpha Paradigm Partners first reported a position in Arcus Biosciences in Q2 2021 and held it in 3 quarters.
  • Alpha Paradigm Partners's Arcus Biosciences position peaked at $2.1M in Q1 2022.
  • 173 funds tracked by Wall St. Rank held Arcus Biosciences as of Q2 2022.

Based on Alpha Paradigm Partners's 13F filing for Q2 2022, filed 15 Aug 2022.